Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to Vote of Security Holders

On June 9, 2025, Unicycive Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 30, 2025 the record date for the Annual Meeting, the holders of the Company's capital stock were entitled to an aggregate of 126, 887,067 votes, comprised of an aggregate of: (i) 120,629,281 votes to which the holders of the Company's shares of outstanding common stock were entitled; (ii) 5,068,068 votes with respect to the 1,816.33102 shares of the Company's outstanding Series A Preferred Stock entitled to vote; and (iii) 1,189,718 votes with respect 1,189.718 shares of the Company's Series B Preferred entitled to vote.

An aggregate of 88,440,393 votes were represented in person or by valid proxies at the Annual Meeting, or approximately 69.70% of the total voting power of the shares of the Company's capital stock entitled to vote. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 30, 2025 are as follows:

Proposal 1. All of the four (4) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the four (4) directors was as follows:

Proposal 2. The appointment of Grassi & Co. CPAs, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2025 was ratified and approved by the stockholders by the votes set forth in the table below:

Proposal 3. The Reverse Stock Split Proposal was approved by the stockholders by the votes set forth in the table below: